Supreme Court's Amgen Ruling Creates Wide-Ranging Implications for Securities Suits and Other Business Litigation


On February 27, 2013, the Supreme Court issued its decision in Amgen, Inc. v. Connecticut Retirement Plans. Justice Ginsburg authored the 6-3 majority opinion affirming the Ninth Circuit’s holding that a securities fraud plaintiff need only plausibly allege — not prove — that the alleged misrepresentations or omissions at issue are material to obtain certification of an investor class. Justice Alito wrote a short concurrence. Justice Thomas wrote the principal dissent, joined by Justice Kennedy and (in large part) Justice Scalia. Justice Scalia also wrote a separate dissent. While the Court removed yet another lower-court-created barrier to class certification, Amgen signals other important defenses to class certification in securities class actions. Although the opinion is limited to the securities fraud context, it highlights the precarious balance at the Supreme Court regarding how stringently to apply Rule 23 in all class actions.

Plaintiff Connecticut Retirement Plans brought a putative class action against Amgen and its officers under §10(b) of the Securities Exchange Act of 1934 and Securities Exchange Commission Rule 10b-5. It alleged that defendants misled investors about the safety, efficacy, and marketing of two of its flagship drugs, causing investors losses when the truth about these drugs came to light. After defendants’ motion to dismiss was denied, plaintiff moved for class certification. Defendants opposed class certification, arguing that a plaintiff must prove the materiality of the alleged misrepresentations to qualify for the class-wide presumption of reliance under the fraud-on-the-market theory to avoid the predominance of individual issues. The district court disagreed, granted plaintiff’s motion, and the Ninth Circuit affirmed.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.